Autism Studies and Related Medical Conditions, January 2009 - TACA

patients with IBS. Since the fermentations of substrates by the intestinal flora may play
a key role in the use of probiotics in the treatment of IBS, fifty patients (24 males, 26
females), mean age 40 years (range = 26-64 years) with IBS, according to Rome II
criteria, were enrolled into the study after informed consensus. Patients were randomly
assigned to receive either the active preparation containing Lactobacillus Plantarum LP0
1 and Bifidocterium Breve BR0 both at a concentration of 5 x 10 CFU/ml, or placebo
powder containing starch identical to the study product, for 4 weeks. To evaluate
treatment efficacy two different scores were considered: Pain score in different
abdominal locations after treatment decreased in probiotics group of 38% versus 18%
(P < 0.05) of placebo group after 14 days and of 52% versus 11% (P < 0.001) after 28
days. The severity score of characteristic IBD symptoms significantly decreased in
probiotic group versus placebo group after 14 days 49.6% versus 9.9% (P < 0.001)
and these data were confirmed after 28 days (44.4% versus 8.5%, P < 0.001). In
conclusion, short-term therapy with Lactobacillus PlantarumLP0 1 and Bifidocterium
Breve BR0 may be considered a promising approach to the therapy for IBS."
210. Di Stefano M et al. Probiotics and functional abdominal bloating. J Clin
Gastroenterol. 2004 Jul;38(6 Suppl):S102-3. PMID: 15220670
"Functional abdominal bloating is a condition dominated by a feeling of abdominal
fullness or bloating and without sufficient criteria for another functional gastrointestinal
disorder. The currently used therapeutic approaches aim to reduce the volume of
intestinal gas, thus increasing intestinal gas elimination or reducing its production.
Some promising results have been obtained by the use of prokinetics, such as
tegaserod and Prostigmine, and by the use of nonabsorbable antibiotics, such as
rifaximin. Another therapeutic approach is represented by the administration of
probiotics to modify the composition of colonic flora and thus the production of
intestinal gas. The authors recently studied the effect of LGG, which proved to be more
effective than placebo in reducing the severity of symptoms."
211. Isolauri E. Dietary modification of atopic disease: Use of probiotics in the
prevention of atopic dermatitis. Curr Allergy Asthma Rep. 2004 Jul;4(4):270-5. PMID:
15175140
"The increased prevalence of atopic diseases, atopic dermatitis, allergic rhinitis, and
asthma has been described as an epidemic. New approaches in the fight against allergic
diseases are called for, the target being the persistence of the atopic T helper 2-skewed
immune responder pattern beyond infancy. Atopic dermatitis, the earliest of these
conditions, might act as a portal for the development of IgE-mediated atopic
manifestations. Abundant evidence implies that specific strains selected from the
healthy gut microbiota exhibit powerful antipathogenic and anti-inflammatory
capabilities, and several targets for the probiotic approach have emerged in atopic
dermatitis: degradation/structural modification of enteral antigens, normalization of the
properties of aberrant indigenous microbiota and of gut barrier functions, regulation of
Autism Studies & Related Medical Conditions – TACA © Page 357